World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
52796
World Ranking
7217
National Ranking
106

Overview

Bruno Sangro is affiliated with the University of Navarra in Spain and focuses their research within the field of Medicine, particularly on hepatology. Their work encompasses the study of liver diseases, cancer immunotherapy, and oncology-related topics, with a significant emphasis on hepatocellular carcinoma (HCC).

Their recent research contributions include several notable papers:

  • BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update (2021), published in Journal of Hepatology
  • Advances in immunotherapy for hepatocellular carcinoma (2021), published in Nature Reviews Gastroenterology & Hepatology
  • Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (2022), published in NEJM Evidence
  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (2020), published in JAMA Oncology
  • Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines (2021), published in Annals of Oncology

Their frequent coauthors include:

  • Patrizia Burra
  • Frank Tacke
  • Masatoshi Kudo
  • Vlad Ratziu
  • Paolo Angeli

Prominent venues where they have published frequently are:

  • Journal of Hepatology
  • Journal of Clinical Oncology
  • Annals of Oncology
  • CardioVascular and Interventional Radiology
  • JHEP Reports

Their research spans multiple subfields including:

  • Hepatology
  • Oncology
  • Epidemiology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology

Main topics of their work cover:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Liver Disease Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Pancreatic and Hepatic Oncology Research
  • Hepatitis C virus research
  • Colorectal Cancer Treatments and Studies

Best Publications

  • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    Anthony B. El-Khoueiry;Bruno Sangro;Thomas Yau;Todd S. Crocenzi

  • BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update.

    M. Reig;A. Forner;J. Rimola;J. Ferrer-Fábrega

  • Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

    Philip J. Johnson;Sarah Berhane;Chiaki Kagebayashi;Shinji Satomura

  • Advances in immunotherapy for hepatocellular carcinoma

    Bruno Sangro;Pablo Sarobe;Sandra Hervás-Stubbs;Ignacio Melero

  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

    Thomas Yau;Yoon Koo Kang;Tae You Kim;Anthony B. El-Khoueiry

  • A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

    Bruno Sangro;Carlos Gomez-Martin;Manuel de la Mata;Mercedes Iñarrairaegui

  • Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

    María Reig;Zoe Mariño;Christie Perelló;Mercedes Iñarrairaegui

  • CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

    T. Yau;J.W. Park;R.S. Finn;A.-L. Cheng

  • Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.

    Luigi Bolondi;Andrew Burroughs;Jean François Dufour;Peterr R. Galle

  • Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

    Bruno Sangro;Livio Carpanese;Roberto Cianni;Rita Golfieri

  • Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization

    J.-L. Raoul;B. Sangro;A. Forner;V. Mazzaferro

  • Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors

    Bruno Sangro;Guillermo Mazzolini;Juan Ruiz;Maite Herraiz

  • Immunological landscape and immunotherapy of hepatocellular carcinoma

    Jesús Prieto;Ignacio Melero;Bruno Sangro

  • New therapies for hepatocellular carcinoma.

    M A Avila;C Berasain;B Sangro;J Prieto

  • Liver disease induced by radioembolization of liver tumors: description and possible risk factors.

    Bruno Sangro;Belen Gil-Alzugaray;Javier Rodriguez;Iosu Sola

  • Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application.

    C. Fillat;M. Carrio;A. Cascante;B. Sangro

  • Radioembolization for hepatocellular carcinoma.

    Bruno Sangro;Mercedes Iñarrairaegui;Jose I. Bilbao

  • Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

    Robin Kate Kelley;Bruno Sangro;William Harris;Masafumi Ikeda

  • Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.

    A. Vogel;E. Martinelli;A. Cervantes;I. Chau

  • Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

    Bruno Sangro;Ignacio Melero;Samir Wadhawan;Richard S Finn

Frequent Co-Authors

Jesús Prieto
Jesús Prieto University of Navarra
Ignacio Melero
Ignacio Melero University of Oxford
Masatoshi Kudo
Masatoshi Kudo Kindai University
Jordi Bruix
Jordi Bruix University of Barcelona
Tim Meyer
Tim Meyer University College London
Matías A. Avila
Matías A. Avila University of Navarra
Winnie Yeo
Winnie Yeo Chinese University of Hong Kong
Jose J.G. Marin
Jose J.G. Marin University of Salamanca
Riad Salem
Riad Salem Northwestern University
Yoon-Koo Kang
Yoon-Koo Kang Asan Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The healthcare field offers a variety of pathways for students interested in medicine but seeking flexible or alternative educational options. For those aspiring to begin their healthcare journey quickly, exploring easiest rn program to get into can be a strategic starting point. These nursing programs typically have more accessible admission requirements, helping you enter the profession sooner.

If you’re interested in the administrative side of healthcare, there are reputable medical billing and coding schools online that provide the flexibility to study from home and financial aid options. This career can offer stable opportunities without direct patient care.

For those concerned about standardized testing, some nursing school without teas test requirements may appeal, allowing you to focus on your studies rather than exam prep.

Lastly, fast-tracking your leadership career is possible by enrolling in accelerated healthcare programs, which can provide advanced credentials in a shorter timeframe.

Exploring these online degree options can help you find a medical or healthcare pathway that fits your strengths, interests, and lifestyle.

Best Scientists Citing Bruno Sangro

Trending Scientists